Finance
Mylan stock dropped 7% after second quarter sales slumped (MYL)
- Mylan’s stock dropped 7.4% shortly after markets opened on Wednesday due to poor second quarter earnings.
- The company’s total revenue for the second quarter was $2.8 billion, down 5% compared to last year. Sales in North America also fell 22%.
- Mylan then announced that it was going to conduct a strategic review of the company, saying it believes it is undervalued. This means the company could be broken up or sold.
- Mylan N.V. is an American pharmaceutical company registered in the Netherlands that makes both generic and specialty drugs. It is best known as the manufacturer of EpiPen.
Continue Reading
-
Entertainment7 days ago
Summer Movie Preview: From ‘Alien’ and ‘Furiosa’ to ‘Deadpool and Wolverine’
-
Entertainment6 days ago
What’s on the far side of the moon? Not darkness.
-
Business6 days ago
How Rubrik’s IPO paid off big for Greylock VC Asheem Chandna
-
Business7 days ago
Thoma Bravo to take UK cybersecurity company Darktrace private in $5B deal
-
Business5 days ago
TikTok faces a ban in the US, Tesla profits drop and healthcare data leaks
-
Business5 days ago
London’s first defense tech hackathon brings Ukraine war closer to the city’s startups
-
Business6 days ago
Photo-sharing community EyeEm will license users’ photos to train AI if they don’t delete them
-
Entertainment7 days ago
‘Challengers’ review: You’re not ready for Zendaya’s horny love-triangle drama